Gabapentin Capsule
Product Images NDC 60760-741

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-741). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba (Gabapentin 60760 741 60)

Label for Gabapentin Capsules USP 300 mg, quantity 60, packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. Manufactured by ScieGen Pharmaceuticals, Inc., Hauppauge, NY. Includes NDC 60760-741-60 and instructions to store at controlled room temperature. Multiple identical product name and strength listings are present on the label panel.*

FDA Label Image

Figure 1 (Image 01)

A line graph comparing mean pain scores over an 8-week period between two groups: placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to 8, and the y-axis represents mean pain score from 0 to 10. The graph includes labels marking a 4-week dose titration period followed by a 4-week fixed dose period, showing pain scores decreasing more in the Gabapentin group than placebo over time.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing mean pain scores over 7 weeks, comparing placebo with Gabapentin dosed at 1800 mg/day and 2400 mg/day. The x-axis represents weeks including a 3-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10. Gabapentin groups show a decrease in pain score over time compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) to Gabapentin (GBP) at dosages of 1800 mg, 2400 mg, and 3600 mg across two studies. The vertical axis shows percentage responders from 0% to 100%. Study 1 shows 12% response for PBO and 29% for GBP 3600 mg. Study 2 shows 14% response for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is marked with p-values less than 0.01 and 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula to calculate creatinine clearance (CLCr), showing the relationship between age, weight, serum creatinine levels, and a factor of 0.85 for female patients. This equation is used to estimate kidney function.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin, showing its cyclohexane ring linked to aminomethyl and carboxymethyl groups.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot graph depicting percentage difference on the vertical axis versus daily dose in milligrams (600, 900, 1200, 1800 mg) on the horizontal axis. The graph compares three studies labeled as Study a, Study b, and Study c, each represented by different shaded squares. Data points for each study show variations in difference percentages at various dosages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.